Targeting CD133 In Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer
2019-06
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Targeting CD133 In Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer
Authors
Published Date
2019-06
Publisher
Type
Thesis or Dissertation
Abstract
An increasing number of men are developing a lethal, non-androgen receptor (AR) driven form of prostate cancer (PCa) known as aggressive variant prostate cancer (AVPC). Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately monitor the disease through imaging. This underscores the critical need to develop improved imaging agents for AVPC. Targeted imaging agents, such as those developed for prostate-specific membrane antigen (PSMA) have made significant progress in imaging metastatic prostate adenocarcinoma; however, numerous studies have shown that non-AR driven prostate cancer does not express PSMA. Thus, there is an urgent unmet need to identify novel antigens and targeted imaging agents for the detection and monitoring of this lethal form of PCa. In these studies, we have identified the pentaspan transmembrane glycoprotein, CD133, as a targetable antigen that is overexpressed on the surface of non-AR driven, neuroendocrine-differentiated prostate cancer. Additionally, we have developed a novel antibody, termed HA10 IgG, which was found to bind to a glycosylation-independent epitope on CD133. HA10 IgG was validated in numerous cell lines and demonstrated similar or more accurate binding to CD133 when compared to a frequently used commercial antibody in vitro. To assess the imaging potential of HA10 IgG, the antibody was labeled for near-infrared and positron emission tomography imaging. Our CD133 probe was validated in imaging studies and shown to be highly selective for CD133-expressing PCa cells, suggesting its potential as a non-invasive imaging agent for lethal, non-AR-driven AVPC.
Keywords
Description
University of Minnesota Ph.D. dissertation. June 2019. Major: Pharmacology. Advisor: Aaron LeBeau. 1 computer file (PDF); xi, 121 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Glumac, Paige M.. (2019). Targeting CD133 In Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/206273.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.